These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38822392)

  • 1. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and assessment of existing guidelines.
    Rufibach K; Beyersmann J; Friede T; Schmoor C; Stegherr R
    Trials; 2024 May; 25(1):353. PubMed ID: 38822392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.
    Stegherr R; Schmoor C; Beyersmann J; Rufibach K; Jehl V; Brückner A; Eisele L; Künzel T; Kupas K; Langer F; Leverkus F; Loos A; Norenberg C; Voss F; Friede T
    Trials; 2021 Jun; 22(1):420. PubMed ID: 34187527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating and comparing adverse event probabilities in the presence of varying follow-up times and competing events.
    Stegherr R; Schmoor C; Lübbert M; Friede T; Beyersmann J
    Pharm Stat; 2021 Nov; 20(6):1125-1146. PubMed ID: 34002935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical issues in the analysis of adverse events in time-to-event data.
    Allignol A; Beyersmann J; Schmoor C
    Pharm Stat; 2016 Jul; 15(4):297-305. PubMed ID: 26929180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study.
    Stegherr R; Beyersmann J; Jehl V; Rufibach K; Leverkus F; Schmoor C; Friede T
    Biom J; 2021 Mar; 63(3):650-670. PubMed ID: 33145854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis.
    Hollaender N; Gonzalez-Maffe J; Jehl V
    Biom J; 2020 May; 62(3):658-669. PubMed ID: 31756032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved confidence intervals for a difference of two cause-specific cumulative incidence functions estimated in the presence of competing risks and random censoring.
    Scosyrev E
    Biom J; 2020 Oct; 62(6):1394-1407. PubMed ID: 32227361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.
    Unkel S; Amiri M; Benda N; Beyersmann J; Knoerzer D; Kupas K; Langer F; Leverkus F; Loos A; Ose C; Proctor T; Schmoor C; Schwenke C; Skipka G; Unnebrink K; Voss F; Friede T
    Pharm Stat; 2019 Mar; 18(2):166-183. PubMed ID: 30458579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doubly robust estimator of risk in the presence of censoring dependent on time-varying covariates: application to a primary prevention trial for coronary events with pravastatin.
    Kawahara T; Shinozaki T; Matsuyama Y
    BMC Med Res Methodol; 2020 Jul; 20(1):204. PubMed ID: 32736528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating a population cumulative incidence under calendar time trends.
    Hansen SN; Overgaard M; Andersen PK; Parner ET
    BMC Med Res Methodol; 2017 Jan; 17(1):7. PubMed ID: 28077076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events in single-arm clinical trials with non-fatal time-to-event efficacy endpoint: from clinical questions to methods for statistical analysis.
    Tassistro E; Bernasconi DP; Valsecchi MG; Antolini L
    BMC Med Res Methodol; 2024 Jan; 24(1):3. PubMed ID: 38172810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A note on variance estimation of the Aalen-Johansen estimator of the cumulative incidence function in competing risks, with a view towards left-truncated data.
    Allignol A; Schumacher M; Beyersmann J
    Biom J; 2010 Feb; 52(1):126-37. PubMed ID: 20140901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-parametric estimation of transition probabilities in non-Markov multi-state models: The landmark Aalen-Johansen estimator.
    Putter H; Spitoni C
    Stat Methods Med Res; 2018 Jul; 27(7):2081-2092. PubMed ID: 29846146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
    Willems S; Schat A; van Noorden MS; Fiocco M
    Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-parametric inference of adverse events under informative censoring.
    Nishikawa M; Tango T; Ogawa M
    Stat Med; 2006 Dec; 25(23):3981-4003. PubMed ID: 16526008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing time-to-event endpoints in cardiology trials: a simulation study to illustrate the importance of an adequate statistical analysis.
    Rauch G; Kieser M; Ulrich S; Doherty P; Rauch B; Schneider S; Riemer T; Senges J
    Eur J Prev Cardiol; 2014 Jan; 21(1):74-80. PubMed ID: 22964966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
    Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
    Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.